Stocktoria

Bio Essence Corp BIOE

OTC · stock · Pharmaceutical Preparations · website · IPO 2022-03-30

Bio Essence Corp statistics & valuation

Market cap$12.7M
P / E14.1×
P / S6.7×
Net margin47.2%
Net debt$57,482
Net debt / EBITDA0.1×
Enterprise value USD$12.7M
EV / EBITDA14.1×
Earnings yield EBIT/EV7.1%

Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-62.20% -72.90% -130.30% -176.20% -404.00% 47.20% 202020212022202320242025
Gross margin (%)
23.70% 33.60% 52.80% 50.30% 67.00% 75.30% 202020212022202320242025
Operating margin (%)
-86.80% -96.60% -82.20% -62.70% -141.80% 47.40% 202020212022202320242025
Return on equity (%)
202020212022202320242025
Shares outstanding
33.0M 33.0M 33.0M 38.0M 38.0M 38.0M 202020212022202320242025
Net debt ($)
$55110 $57482 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-32.30% -38.10% -52.30% -35.20% -465.70% 212.10% 202020212022202320242025
Free cash flow margin (%)
-77.20% -159.20% -113.70% -186.60% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$0.02 -$0.02 -$0.03 -$0.03 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Gross margin75.3%67.0%50.3%52.8%33.6%23.7%
Operating margin47.4%-141.8%-62.7%-82.2%-96.6%-86.8%
Net margin47.2%-404.0%-176.2%-130.3%-72.9%-62.2%
FCF margin——-186.6%-113.7%-159.2%-77.2%
Return on assets212.1%-465.7%-35.2%-52.3%-38.1%-32.3%
Return on equity-43.2%44.1%58.5%25.0%26.7%33.5%
Debt / equity-0.03×-0.02×————
Current ratio0.170.100.120.060.100.17

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.